Abstract
Bone destruction or osteolysis marked by excessive osteoclastic bone resorption is a very common medical condition. Identification of agents that can effectively suppress excessive osteoclast formation and function is crucial for prevention and treatment of osteolytic conditions such as periprosthetic joint infection and periprosthetic loosening. Luteoloside, a flavonoid, is a natural bioactive compound with anti-inflammation and anti-tumor properties. However, the effect of Luteoloside on inflammation-induced osteolysis is unknown. Here, we found that Luteoloside exhibited a strong inhibitory effect on lipopolysaccharide (LPS)-induced osteolysis in vivo. In addition, Luteoloside suppressed RANKL-induced osteoclast differentiation and abrogated bone resorption in a dose-dependent manner. Further, we found that the anti-osteoclastic and anti-resorptive actions of Luteoloside are mediated via blocking NFATc1 activity and the attenuation of RANKL-mediated Ca2+ signaling as well as NF-κB and MAPK pathways. Taken together, this study shows that Luteoloside may be a potential therapeutic agent for osteolytic bone diseases associated with abnormal osteoclast formation and function in inflammatory conditions.
| Original language | English |
|---|---|
| Pages (from-to) | 1723-1735 |
| Number of pages | 13 |
| Journal | Journal of Cellular Physiology |
| Volume | 233 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Feb 2018 |
Fingerprint
Cite this
}
Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades. / Song, Fangming; Wei, Chengming; Zhou, Lin; Qin, An; Yang, Mingli; Tickner, Jennifer; Huang, Yuanjiao; Zhao, Jinmin; Xu, Jiake.
In: Journal of Cellular Physiology, Vol. 233, No. 2, 01.02.2018, p. 1723-1735.Research output: Contribution to journal › Article
TY - JOUR
T1 - Luteoloside prevents lipopolysaccharide-induced osteolysis and suppresses RANKL-induced osteoclastogenesis through attenuating RANKL signaling cascades
AU - Song, Fangming
AU - Wei, Chengming
AU - Zhou, Lin
AU - Qin, An
AU - Yang, Mingli
AU - Tickner, Jennifer
AU - Huang, Yuanjiao
AU - Zhao, Jinmin
AU - Xu, Jiake
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Bone destruction or osteolysis marked by excessive osteoclastic bone resorption is a very common medical condition. Identification of agents that can effectively suppress excessive osteoclast formation and function is crucial for prevention and treatment of osteolytic conditions such as periprosthetic joint infection and periprosthetic loosening. Luteoloside, a flavonoid, is a natural bioactive compound with anti-inflammation and anti-tumor properties. However, the effect of Luteoloside on inflammation-induced osteolysis is unknown. Here, we found that Luteoloside exhibited a strong inhibitory effect on lipopolysaccharide (LPS)-induced osteolysis in vivo. In addition, Luteoloside suppressed RANKL-induced osteoclast differentiation and abrogated bone resorption in a dose-dependent manner. Further, we found that the anti-osteoclastic and anti-resorptive actions of Luteoloside are mediated via blocking NFATc1 activity and the attenuation of RANKL-mediated Ca2+ signaling as well as NF-κB and MAPK pathways. Taken together, this study shows that Luteoloside may be a potential therapeutic agent for osteolytic bone diseases associated with abnormal osteoclast formation and function in inflammatory conditions.
AB - Bone destruction or osteolysis marked by excessive osteoclastic bone resorption is a very common medical condition. Identification of agents that can effectively suppress excessive osteoclast formation and function is crucial for prevention and treatment of osteolytic conditions such as periprosthetic joint infection and periprosthetic loosening. Luteoloside, a flavonoid, is a natural bioactive compound with anti-inflammation and anti-tumor properties. However, the effect of Luteoloside on inflammation-induced osteolysis is unknown. Here, we found that Luteoloside exhibited a strong inhibitory effect on lipopolysaccharide (LPS)-induced osteolysis in vivo. In addition, Luteoloside suppressed RANKL-induced osteoclast differentiation and abrogated bone resorption in a dose-dependent manner. Further, we found that the anti-osteoclastic and anti-resorptive actions of Luteoloside are mediated via blocking NFATc1 activity and the attenuation of RANKL-mediated Ca2+ signaling as well as NF-κB and MAPK pathways. Taken together, this study shows that Luteoloside may be a potential therapeutic agent for osteolytic bone diseases associated with abnormal osteoclast formation and function in inflammatory conditions.
KW - luteoloside
KW - osteoclast
KW - osteolysis
KW - RANKL
UR - http://www.scopus.com/inward/record.url?scp=85032971547&partnerID=8YFLogxK
U2 - 10.1002/jcp.26084
DO - 10.1002/jcp.26084
M3 - Article
VL - 233
SP - 1723
EP - 1735
JO - Journal Cellular Physiology
JF - Journal Cellular Physiology
SN - 0021-9541
IS - 2
ER -